{"title":"新的BA.2.75亚变体会导致新一轮COVID-19浪潮吗?","authors":"Suman Kumar Ray, Sukhes Mukherjee","doi":"10.2174/1871526523666230302103609","DOIUrl":null,"url":null,"abstract":"<p><p>The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave?\",\"authors\":\"Suman Kumar Ray, Sukhes Mukherjee\",\"doi\":\"10.2174/1871526523666230302103609\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.</p>\",\"PeriodicalId\":13678,\"journal\":{\"name\":\"Infectious disorders drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871526523666230302103609\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230302103609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave?
The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.
期刊介绍:
Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.